Tirzepatide, also known as LY 3298176, is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist. Tezeparatide has greater affinity for GIP receptors than for GLP-1 receptors, and this dual agonist behavior has been shown to reduce high levels of hypertension to a greater extent than selective GLP-1 receptor agonists. blood sugar. Signaling studies indicate that tezepatide mimics the actions of native GIP at GIP receptors. Tezepatide is approved to improve glycemic control in adults with type 2 diabetes as a supplement to diet and exercise.